# Academic & Research Institution Partnerships

**Document Version**: 1.0
**Last Updated**: November 8, 2025
**Owner**: Chief Science Officer
**Purpose**: Strategic framework for partnering with leading academic medical centers and research institutions‚Äîaccelerating AATD research, improving clinical care, and establishing Foundation as essential collaborator in AATD ecosystem

---

## üìã Table of Contents

1. [Partnership Overview](#partnership-overview)
2. [Target Institutions](#target-institutions)
3. [Partnership Models](#partnership-models)
4. [Research Collaboration Framework](#research-collaboration-framework)
5. [Clinical Center of Excellence Program](#clinical-center-of-excellence-program)
6. [Data Sharing & Registry Integration](#data-sharing--registry-integration)
7. [Training & Education Programs](#training--education-programs)
8. [Funding Mechanisms](#funding-mechanisms)
9. [Success Metrics](#success-metrics)
10. [Implementation Roadmap](#implementation-roadmap)

---

## Partnership Overview

### Why Academic Partnerships Matter

**Research Acceleration**:

- Academic institutions have infrastructure (labs, equipment, IRBs‚ÄîFoundation leverages existing assets vs. building from scratch)
- Top researchers work at universities (Harvard, Stanford, Cleveland Clinic‚ÄîFoundation gains access to best minds)
- Clinical trial sites (academic medical centers enroll patients‚ÄîFoundation-funded trials run faster)

**Clinical Care Improvement**:

- AATD expertise concentrated (10-20 centers nationwide have deep expertise‚ÄîMayo, National Jewish, UCSF)
- Care standardization (Foundation partners with centers to establish best practices‚Äîdisseminate to community physicians)
- Training next generation (Foundation funds fellowships‚Äîensure future supply of AATD specialists)

**Patient Access**:

- Patients trust academic centers (brand recognition‚Äî"If Cleveland Clinic says it, it must be good")
- Foundation partners with centers where patients already go (meet patients where they are‚Äîvs. creating parallel infrastructure)

**Mutual Benefit**:

- Foundation gains: Research capacity, clinical expertise, patient access, credibility
- Institutions gain: Funding, patient registry access, collaborative opportunities, community partner

---

### Strategic Priorities

**Top 3 Partnership Goals**:

1. **Research Funding**: $1M-$3M/year to academic AATD research by Year 5 (become major funder‚Äîshape research agenda)
2. **Clinical Network**: Designate 10-15 AATD Centers of Excellence by Year 5 (quality care standards, data sharing)
3. **Training Pipeline**: Fund 5-10 AATD fellowships/year by Year 5 (pulmonary, genetics, hepatology‚Äîensure next generation of experts)

---

## Target Institutions

### Tier 1: Premier AATD Centers (Deep Existing Expertise)

**1. National Jewish Health (Denver, CO)**

- **Why Target**: #1 respiratory hospital in US (US News‚Äîconsistent top ranking), Robert Sandhaus MD (AATD legend‚Äî50+ years experience)
- **AATD Program**: Dedicated AATD clinic, augmentation infusion center, research program (natural history studies, clinical trials)
- **Current Research**: Alpha-1 Registry (10,000+ patients‚Äîlongest-running AATD registry), gene therapy trials, novel therapies
- **Partnership Opportunities**:
  - Co-fund registry expansion ($100K/year‚Äîadd genetic data, biospecimens)
  - Sponsor research fellows ($75K/year‚Äîtrain next generation)
  - Joint conferences (host annual AATD Scientific Summit‚ÄîFoundation + National Jewish)

---

**2. Cleveland Clinic (Cleveland, OH)**

- **Why Target**: Top pulmonology program, James Stoller MD (AATD researcher‚Äîauthor of 100+ AATD papers), local to Foundation (if based in Ohio)
- **AATD Program**: AATD Clinic (200+ patients), augmentation therapy, lung transplant program (for end-stage AATD)
- **Current Research**: AATD epidemiology, quality of life studies, disparities in diagnosis
- **Partnership Opportunities**:
  - Fund AATD research chair ($1M endowment‚Äînamed professorship, attract/retain top researcher)
  - Patient navigation program (Foundation funds navigator at Clinic‚Äîsmooth referrals, improve outcomes)
  - CME programs (Foundation sponsors AATD education for community physicians‚Äîdisseminate best practices)

---

**3. University of Florida (Gainesville, FL)**

- **Why Target**: Mark Brantly MD (AATD pioneer‚Äîgene therapy researcher, augmentation therapy trials)
- **AATD Program**: AATD Clinic, research program (AAV gene therapy, novel augmentation formulations), biorepository
- **Current Research**: Gene therapy (AAV-AAT‚ÄîPhase 1/2 trials), protein structure studies, ZZ protein rescue
- **Partnership Opportunities**:
  - Co-fund gene therapy trials ($500K‚Äîpatient recruitment, follow-up, biospecimens)
  - Biospecimen collection (Foundation patients donate samples‚Äîstored at UF biorepository, available for research)
  - Training program (Foundation funds annual AATD short course for fellows‚Äî1-week intensive, didactics + clinical)

---

**4. Medical University of South Carolina (Charleston, SC)**

- **Why Target**: Charlie Strange MD (AATD clinical trials expert‚Äîaugmentation therapy trials, outcomes research)
- **AATD Program**: AATD Clinic, augmentation center, lung transplant (AATD patients), clinical trial site
- **Current Research**: Augmentation therapy outcomes, lung transplant in AATD, quality of life
- **Partnership Opportunities**:
  - Clinical trial collaboration (Foundation funds trial coordination‚Äîfaster enrollment)
  - Liver disease research (MUSC has strong hepatology‚Äîpartner on AATD liver studies)

---

**5. Oregon Health & Science University (Portland, OR)**

- **Why Target**: Kevin Flaherty MD (ILD expert‚ÄîAATD overlaps with interstitial lung disease), West Coast presence
- **AATD Program**: AATD Clinic (smaller but growing), research program
- **Partnership Opportunities**:
  - Expand clinic (Foundation funds clinic coordinator‚Äîgrow patient volume, improve access)
  - West Coast hub (Foundation's West Coast "headquarters"‚Äîevents, support groups, clinical trials)

---

### Tier 2: Emerging AATD Programs (Growth Potential)

**6. University of Pennsylvania (Philadelphia, PA)**

- AATD Program: Growing (not historically major center, but strong pulmonology + gene therapy expertise)
- Partnership: Co-develop gene therapy program (Penn has gene therapy institute‚Äîpartner on AATD gene therapy research)

**7. Washington University (St. Louis, MO)**

- AATD Program: Jeffrey Teckman MD (pediatric AATD liver disease expert‚Äîchildren's hospital)
- Partnership: Pediatric AATD research (fund liver disease studies‚Äîcomplement adult lung research at other centers)

**8. University of Texas Southwestern (Dallas, TX)**

- AATD Program: Emerging (South has large AATD population‚Äîunderdiagnosed, Foundation could help build program)
- Partnership: Clinical program development (Foundation funds startup‚Äîclinic coordinator, equipment, marketing, grow patient base)

---

### Tier 3: Academic Powerhouses (Not AATD-Focused, But High Potential)

**9. Johns Hopkins (Baltimore, MD)**

- Partnership: Leverage genetics expertise (Hopkins has #1 genetics program‚Äîrecruit to study AATD modifier genes, GWAS studies)

**10. Stanford University (Palo Alto, CA)**

- Partnership: Leverage tech/innovation (Stanford entrepreneurial‚Äîpartner on diagnostics, digital health, AI for AATD)

**11. Mayo Clinic (Rochester, MN; Scottsdale, AZ; Jacksonville, FL)**

- Partnership: Clinical care network (Mayo's 3 sites‚ÄîFoundation designates as Centers of Excellence, standardize care across network)

---

## Partnership Models

### Model 1: Research Grant Partnership

**Structure**:

- Foundation issues RFP (Request for Proposals‚Äîannual cycle, specific priorities e.g., "gene therapy," "diagnostics," "liver disease")
- Academic investigators submit proposals (2-5 pages‚Äîspecific aims, methods, budget, timeline)
- Foundation Scientific Advisory Board reviews (score, rank, fund top 5-10 proposals)
- Grants awarded ($50K-$250K per project, 1-3 years)

**Terms**:

- Milestone-based funding (release funds in stages‚ÄîYear 1 upfront, Year 2 after progress report, final payment upon publication)
- IP rights (Foundation co-owns‚Äînegotiate case-by-case, Foundation gets right of first refusal on commercialization)
- Acknowledgment (all publications acknowledge Foundation‚Äîbrand visibility, donor stewardship)
- Data sharing (raw data deposited in Foundation registry‚Äîopen access for other researchers)

**Example**:

- Foundation funds $150K to MUSC for "Augmentation Therapy Outcomes Study" (3-year study, 200 patients, lung function + quality of life)
- Year 1: $50K (patient enrollment, baseline data collection)
- Year 2: $50K (after 50% enrollment‚Äîprogress report required)
- Year 3: $50K (after publication in major journal‚Äîe.g., AJRCCM, Thorax)

---

### Model 2: Center of Excellence Designation

**Structure**:

- Foundation designates 10-15 academic centers as "AATD Centers of Excellence" (seal of approval‚Äîquality standards)
- Centers must meet criteria:
  - Dedicated AATD Clinic (at least 100 AATD patients under care)
  - Multidisciplinary team (pulmonology, genetics, hepatology, social work‚Äîcomprehensive care)
  - Active research program (clinical trials, publications, Foundation-funded research)
  - Data sharing (submit patient data to Foundation registry‚Äîde-identified)
  - Education (train fellows, CME for community physicians‚Äîdisseminate knowledge)

**Benefits to Centers**:

- Designation fee ($25K-$50K/year‚ÄîFoundation pays center for meeting standards, submitting data)
- Marketing support (Foundation lists Centers on website‚Äîpatient referrals increase)
- Research opportunities (Centers get priority for Foundation-funded trials‚Äîeasier recruitment, more funding)

**Benefits to Foundation**:

- Quality care (patients directed to best centers‚Äîbetter outcomes)
- Data (standardized data collection across 10-15 sites‚Äîrobust registry, research-ready)
- Network (convene annual Center of Excellence meeting‚Äîshare best practices, collaborative research)

**Example**:

- Cleveland Clinic designated as Center of Excellence (meets all criteria‚Äî100+ patients, multidisciplinary, research-active)
- Foundation pays $50K/year (supports clinic coordinator, data submission costs)
- Clinic submits data on 150 patients to Foundation registry (demographics, lung function, treatment, outcomes‚Äîannually updated)
- Foundation refers 20-30 patients/year to Cleveland Clinic (from registry, support groups‚Äîpatients seeking second opinion, clinical trials)

---

### Model 3: Endowed Chair or Fellowship

**Structure**:

- Foundation endows professorship or fellowship at academic center ($1M-$2M endowment‚Äîgenerates $50K-$100K/year in perpetuity)
- Endowment supports salary + research funds for AATD-focused faculty or fellows

**Types**:

**Endowed Chair** ($2M endowment):

- Names senior faculty position (e.g., "Mark Egly Chair in Alpha-1 Antitrypsin Research" at Cleveland Clinic)
- Attracts/retains top researcher (prestigious title, research funds‚Äîcompetitive advantage in recruitment)
- Perpetual (chair exists forever‚ÄîFoundation's legacy)

**Fellowship** ($1M endowment):

- Funds 1-2 year fellowship for pulmonary/genetics fellow (clinical + research training in AATD)
- Trains next generation (ensure future supply of AATD experts‚Äîcurrently only 10-20 true experts nationwide)
- Annual (supports 1 fellow/year in perpetuity‚Äî20+ fellows over 20 years = significant workforce development)

**Example**:

- Foundation raises $2M (major donor campaign‚Äî"Endow the Mark Egly Chair")
- Chair established at University of Florida (Mark Brantly MD named as inaugural chair‚Äîor recruit new researcher if he retires)
- Chair receives $100K/year (salary support + research funds‚Äîrecruits lab staff, buys equipment, runs pilot studies)
- Chair's research leads to gene therapy breakthrough (Foundation's investment pays off‚Äîcure discovered)

---

### Model 4: Joint Clinical Trial

**Structure**:

- Foundation + academic center co-sponsor clinical trial (Foundation funds, center conducts)
- Trial tests Foundation priority (e.g., inhaled AAT, subcutaneous AAT, gene therapy)

**Roles**:

- **Foundation**: Provide funding ($500K-$2M), recruit patients (via registry), disseminate results (community engagement)
- **Academic Center**: Design trial (write protocol, IRB approval), enroll patients (clinic patients + Foundation referrals), analyze data (statistics, publication)

**IP & Data**:

- Co-owned (Foundation + institution‚Äîshare rights to any discoveries, patents)
- Data shared (results posted on ClinicalTrials.gov, raw data in Foundation registry‚Äîtransparency)

**Example**:

- Foundation funds $1M trial at MUSC: "Subcutaneous AAT vs. IV AAT" (Phase 2, 100 patients, 6 months)
- MUSC enrolls 100 patients (50 from clinic, 50 from Foundation registry referrals)
- Trial shows SubQ non-inferior to IV (same AAT levels, patient preference higher for SubQ)
- Foundation + MUSC co-publish in AJRCCM (high-impact‚Äîchanges clinical practice)
- Foundation advocates for FDA approval (uses trial data‚ÄîSubQ AAT approved 2 years later)

---

## Research Collaboration Framework

### Foundation Research Priorities (Guide Partnership Focus)

**Priority 1: Diagnostics** (20% of research budget):

- Rapid testing device (point-of-care AAT test‚Äîsee separate document)
- Genetic testing simplification (at-home kits, 23andMe partnership‚Äîsee separate document)
- Machine learning (identify undiagnosed AATD in EHRs‚Äîpredictive algorithms)

**Priority 2: Therapeutics** (40% of research budget):

- Gene therapy (AAV, CRISPR‚Äîcure vs. chronic management)
- Novel delivery (subcutaneous, inhaled, sustained-release AAT‚Äîsee separate document)
- ZZ protein rescue (chaperones, autophagy‚Äîsee separate document)

**Priority 3: Outcomes Research** (20% of research budget):

- Augmentation therapy effectiveness (real-world data‚Äîregistry analysis)
- Quality of life (patient-reported outcomes‚Äîtreatment burden, mental health)
- Health economics (cost-effectiveness‚Äîsupport insurance coverage arguments)

**Priority 4: Basic Science** (20% of research budget):

- Protein structure (understand ZZ misfolding‚Äîinform drug design)
- Modifier genes (why some ZZ patients have severe disease, others mild?‚Äîidentify protective factors)
- Lung microbiome (role in AATD progression‚Äînovel therapeutic targets)

---

### Annual Research Cycle

**January-February: RFP Release**

- Foundation announces research priorities (e.g., "2026 focus: gene therapy, diagnostics")
- RFP posted on website (application guidelines, budget limits, deadlines)
- Letters of intent due (2-page brief‚Äîinvestigators propose idea, Foundation pre-screens for fit)

**March: Invited Applications**

- Foundation invites 15-20 LOIs to submit full proposals (narrow field‚Äîsave reviewers' time)
- Full proposals due April 1 (10 pages max‚Äîspecific aims, methods, budget, biosketches)

**April-May: Peer Review**

- Scientific Advisory Board reviews (8-10 experts‚ÄîAATD researchers, clinicians, patient advocates)
- Score proposals (1-9 scale‚Äîimpact, innovation, feasibility)
- In-person review meeting (discuss top proposals, debate, rank)

**June: Award Decisions**

- Foundation Board approves awards (SAB recommendations‚Äîfinal decision on funding)
- Notify applicants (funded vs. not funded‚Äîfeedback provided to all)

**July-August: Contract Negotiation**

- Legal agreements (grant terms, IP rights, milestones, reporting requirements)
- Funds released (usually September 1‚Äîstart of grant year)

**Ongoing: Monitoring**

- Annual progress reports (investigators submit‚ÄîFoundation reviews, ensures milestones met)
- Site visits (Foundation staff visit labs‚Äîmeet researchers, see progress, build relationships)

**End of Grant: Publication & Dissemination**

- Manuscript required (publish in peer-reviewed journal‚Äînon-negotiable)
- Foundation promotes (press release, newsletter, social media‚Äîdonor stewardship, show impact)

---

## Clinical Center of Excellence Program

### Accreditation Standards

**Clinical Criteria**:

- ‚úÖ Minimum 100 AATD patients under active care
- ‚úÖ Multidisciplinary team (pulmonologist + geneticist or genetic counselor + hepatologist + social worker/patient navigator)
- ‚úÖ Augmentation therapy on-site (infusion center‚Äîdon't require patients to go elsewhere)
- ‚úÖ Spirometry, CT scan access (diagnostic capabilities‚Äîpatients can get full workup at center)

**Research Criteria**:

- ‚úÖ Participate in at least 1 AATD clinical trial/year (demonstrate research capability)
- ‚úÖ Publish AATD research (at least 1 paper/year‚Äîshows active scholarly work)
- ‚úÖ Enroll patients in Foundation registry (all patients offered registry participation‚Äîdata contribution)

**Education Criteria**:

- ‚úÖ Train fellows or residents (expose trainees to AATD‚Äîbuild workforce)
- ‚úÖ Offer CME (at least 1 AATD-focused CME/year‚Äîeducate community physicians)

**Data Sharing Criteria**:

- ‚úÖ Submit data to Foundation registry (quarterly updates‚Äîdemographics, lung function, hospitalizations, treatments)
- ‚úÖ Participate in annual Center survey (operations, volumes, outcomes‚Äîbenchmark performance)

---

### Benefits of Designation

**For Centers**:

- **Funding**: $50K/year stipend (covers data coordinator salary, offset data submission costs)
- **Patient Referrals**: Listed on Foundation website (patients search "AATD Centers near me"‚Äîdrive clinic volume)
- **Research Access**: Priority for Foundation-funded trials (easier to enroll patients‚Äîmore grant funding)
- **Networking**: Annual Center of Excellence Summit (meet peer centers, share best practices, collaborative research)
- **Brand**: "AATD Center of Excellence" seal (use in marketing‚Äîprestigious, attracts patients)

**For Foundation**:

- **Quality**: Patients receive excellent care (standardized, evidence-based‚Äîbetter outcomes)
- **Data**: Robust registry (10-15 centers √ó 100+ patients = 1,000-1,500 patients in registry)
- **Research**: Trial-ready sites (when Foundation funds trial‚ÄîCenters enroll quickly, protocol-ready)
- **Education**: Centers train next generation (fellows become future AATD experts‚Äîsustainable workforce)

---

### Annual Center of Excellence Summit

**Format**: 2-day meeting (100-150 attendees‚Äîcenter leaders, researchers, Foundation staff, pharma partners)

**Day 1: Clinical Best Practices**

- Panel: "Managing AATD Exacerbations" (center directors share protocols‚Äîstandardize care)
- Workshop: "Liver Disease Screening in AATD" (hepatologists lead‚Äîimprove liver care)
- Data session: "Registry Insights" (Foundation presents aggregate data‚Äîcenters see how they compare to peers)

**Day 2: Research Collaboration**

- Grant awardee presentations (Foundation-funded researchers present findings‚Äîtransparency, inspire new ideas)
- Breakout: "Multi-Center Trial Design" (plan collaborative studies‚Äîleverage network for large trials)
- Strategic planning: "Foundation Research Priorities 2027" (centers provide input‚Äîalign Foundation priorities with clinical needs)

**Outcome**: White papers (co-authored by centers + Foundation‚Äî"AATD Care Standards," "Research Gaps"‚Äîpublish, disseminate)

---

## Data Sharing & Registry Integration

### Why Data Sharing Matters

**Research Acceleration**:

- Large datasets enable discovery (1,000+ patients reveal patterns‚Äîsingle center with 50 patients cannot)
- Multi-center trials faster (if 10 centers participate‚Äîenroll 300 patients in 6 months vs. 3 years at single site)
- Real-world evidence (registry data supplements clinical trials‚Äîbroader generalizability)

**Quality Improvement**:

- Benchmarking (centers compare outcomes‚Äî"Why does Cleveland Clinic have lower hospitalization rate? Let's learn from them.")
- Identify best practices (data-driven‚Äînot opinion-based)

**Patient Benefit**:

- Personalized care (algorithms predict who will progress faster‚Äîintensify monitoring, early intervention)

---

### Data Collection Protocol

**Minimum Dataset** (All Centers Submit Annually):

- **Demographics**: Age, sex, race/ethnicity, zip code
- **Genetics**: Genotype (ZZ, SZ, MZ, etc.), family history
- **Clinical**: FEV1, FVC, CT emphysema score, liver enzymes (AST, ALT), BMI
- **Treatment**: Augmentation therapy (yes/no, start date), lung transplant (yes/no, date)
- **Outcomes**: Exacerbations/year, hospitalizations/year, mortality

**Enhanced Dataset** (Optional, Incentivized with Bonus $25K):

- **Biospecimens**: Blood, DNA, sputum (stored in biorepository‚Äîfuture research)
- **Imaging**: CT scans uploaded (centrally analyzed‚Äîstandardized emphysema quantification)
- **Patient-Reported Outcomes**: Quality of life (SGRQ, SF-36), symptoms (CAT score), treatment satisfaction

**Data Security**:

- HIPAA-compliant (de-identified data‚Äîno names, MRNs, only coded IDs)
- Secure portal (REDCap or similar‚Äîencrypted, audit trails)
- Data use agreements (centers + Foundation sign‚Äîdefine permitted uses, prevent misuse)

---

### Registry Governance

**Data Access**:

- **Centers**: Access own center's data (real-time‚Äîmonitor clinic performance)
- **Foundation**: Access aggregate data (de-identified across all centers‚Äîresearch, reports)
- **External Researchers**: Request access (proposal required‚ÄîFoundation Scientific Advisory Board approves, ensures scientifically sound)

**Publication Policy**:

- Centers can publish own data (no permission needed‚Äîencourage dissemination)
- Multi-center publications (requires all contributing centers' approval‚Äîco-authorship offered)
- Foundation publications (requires SAB review‚Äîensure quality, protect centers' interests)

---

## Training & Education Programs

### AATD Fellowship Program

**Goal**: Train 5-10 fellows/year by Year 5 (address workforce shortage‚Äîcurrently only 10-20 true AATD experts nationwide)

**Fellowship Structure**:

- **Duration**: 1-2 years (post-residency or post-pulmonary fellowship)
- **Sites**: Centers of Excellence (University of Florida, National Jewish, Cleveland Clinic‚Äîfellows rotate, gain diverse experience)
- **Curriculum**:
  - **Clinical** (60%): AATD clinic (diagnose, treat, counsel patients), augmentation infusion center, lung transplant (if site has program)
  - **Research** (30%): Design and conduct AATD study (registry analysis, pilot trial, lab research‚Äîfellows produce publication)
  - **Advocacy** (10%): Work with Foundation (attend patient conferences, legislative visits‚Äîunderstand patient advocate perspective)

**Funding**:

- Foundation provides $75K/year (fellow salary‚Äîcompetitive with other subspecialty fellowships)
- Host center provides benefits + research support ($25K‚Äîtotal package $100K)

**Application**:

- Open to pulmonary fellows, genetics fellows, hepatology fellows (AATD is multidisciplinary‚Äîrecruit from multiple specialties)
- 5-10 positions/year (by Year 5‚Äîramp up from 1-2/year initially)

**Expected Outcome**:

- 50+ fellows trained over 10 years (many become AATD clinic directors‚Äîdouble or triple number of expert centers nationwide)

---

### CME Programs (Continuing Medical Education for Community Physicians)

**Need**: Most physicians don't know about AATD (rarely taught in med school, residency‚Äîprimary care physicians miss diagnoses)

**Program**: Foundation sponsors CME courses (1-2 hour modules‚Äîonline or in-person)

**Topics**:

- "AATD 101 for Primary Care" (when to test, how to test, when to refer)
- "Managing AATD in Pulmonary Practice" (augmentation therapy, monitoring, complications)
- "Liver Disease in AATD" (for gastroenterologists‚Äîwhen to screen, how to manage)

**Delivery**:

- Online modules (free CME credit‚Äîphysicians take at own pace, Foundation-branded)
- Grand Rounds (Foundation funds speaker to present at community hospitals‚ÄîCleveland, Columbus, Akron‚Äîreach 50-100 physicians per session)
- Annual conference (Foundation hosts CME track‚Äî100-200 community physicians attend, learn about AATD)

**Impact**:

- 1,000+ physicians educated/year by Year 5 (each diagnoses 1-2 AATD patients‚Äî1,000-2,000 new diagnoses/year attributable to Foundation education)

---

## Funding Mechanisms

### Foundation Investment by Category

**Research Grants** ($1M-$2M/year by Year 5):

- Pilot grants: $50K √ó 10 = $500K (seed new ideas‚Äîhigh risk, high reward)
- Full grants: $150K √ó 5 = $750K (established researchers‚Äîlarger studies)
- Multi-center trials: $500K √ó 1 = $500K (collaborative‚Äîmajor impact potential)

**Center of Excellence Stipends** ($500K-$750K/year by Year 5):

- 10-15 centers √ó $50K = $500K-$750K (data submission, quality care‚Äîinfrastructure investment)

**Fellowships** ($375K-$750K/year by Year 5):

- 5-10 fellows √ó $75K = $375K-$750K (workforce development‚Äîlong-term strategic)

**CME/Education** ($100K-$200K/year by Year 5):

- Online modules: $50K (development, hosting, accreditation)
- Grand Rounds: $25K (speaker fees, travel‚Äî25 sessions/year)
- Annual conference: $50K (CME track‚Äîspeakers, materials, accreditation)

**Total Academic Partnership Investment**: $2M-$3.7M/year by Year 5 (40-50% of Foundation's budget‚Äîresearch-focused model)

---

## Success Metrics

### Research Output Metrics

**Publications**:

- Year 3: 10 peer-reviewed papers (Foundation-funded research)
- Year 5: 25 papers/year (mature research program‚Äîhigh productivity)

**Impact**:

- Citations (measure influence‚ÄîFoundation-funded papers cited 500+ times/year by Year 5)
- Journal quality (publish in top journals‚ÄîAJRCCM, NEJM, Nature Medicine‚Äî50% in top quartile)

---

### Clinical Impact Metrics

**Centers of Excellence**:

- Year 3: 5 centers designated (early adopters‚Äîprove model)
- Year 5: 15 centers (national network‚Äîcoverage in all major regions)

**Patient Access**:

- 80% of US AATD patients within 2 hours of Center of Excellence (geographic coverage‚Äîreduce travel burden)

**Registry Growth**:

- Year 3: 1,000 patients enrolled (from Centers of Excellence‚Äî10 centers √ó 100 patients)
- Year 5: 3,000 patients (15 centers √ó 200 patients‚Äîsome centers grow beyond 100)

---

### Training Metrics

**Fellows**:

- Year 3: 3 fellows/year (pilot cohorts‚ÄîUniversity of Florida, National Jewish, Cleveland Clinic)
- Year 5: 7-10 fellows/year (expand to more sites)

**CME Reach**:

- Year 3: 500 physicians educated (CME modules, Grand Rounds)
- Year 5: 1,500 physicians/year (scaled program‚Äîonline reach)

---

## Implementation Roadmap

### Year 1: Foundation Building

**Q1-Q2**:

- Form Scientific Advisory Board (recruit 8-10 AATD experts‚Äîguide research priorities)
- Develop RFP process (application templates, review criteria, funding terms)

**Q3**:

- Launch first RFP (pilot‚Äî$250K total, 5 grants @ $50K each)
- Identify 3-5 target Centers of Excellence (National Jewish, Cleveland Clinic, University of Florida‚Äîinitiate conversations)

**Q4**:

- Award first grants (announce‚Äîpress release, donor stewardship)
- Sign first Center of Excellence (pilot designation‚ÄîCleveland Clinic or National Jewish)

---

### Year 2: Program Expansion

**Q1**:

- Second RFP cycle ($500K‚Äî10 grants)
- Recruit 2-3 more Centers (total 3-5 Centers)

**Q2**:

- Launch fellowship program (1-2 fellows‚Äîpilot at University of Florida)

**Q3**:

- First CME module (online‚Äî"AATD 101 for Primary Care")

**Q4**:

- Annual grantee meeting (bring together all Foundation-funded researchers‚Äîshare results, foster collaboration)

---

### Year 3: Maturity

**Q1-Q4**:

- Scale research program ($1M/year‚Äî20 grants)
- Expand Centers of Excellence (10 total‚Äîgeographic diversity)
- Fellowship program (5 fellows/year‚Äîmultiple sites)
- CME program (3 modules, 20 Grand Rounds‚Äîreach 500 physicians)

---

### Year 5: Optimization

**Research**: $2M/year (Foundation is top 3 AATD research funders‚Äîafter NIH, pharma)
**Centers**: 15 designated (national network‚Äîpatient access improved)
**Fellowships**: 10/year (doubling AATD workforce‚Äîtransformational)
**CME**: 1,500 physicians educated/year (diagnosis rates increase‚Äî"find the missing 90%")

---

## Summary

**Academic Partnerships = Research Engine + Clinical Network**:

- ‚úÖ **Research**: $2M/year by Year 5 (fund breakthroughs‚Äîgene therapy, diagnostics, treatments)
- ‚úÖ **Clinical Network**: 15 Centers of Excellence (quality care, standardized, data-driven‚Äîbetter outcomes)
- ‚úÖ **Training**: 10 fellows/year (double AATD workforce‚Äîensure future experts)
- ‚úÖ **Education**: 1,500 physicians/year (improve diagnosis‚Äîfind undiagnosed patients)

**10-Year Vision**: Foundation-funded research leads to cure (gene therapy approved, Foundation receives royalties‚Äîperpetual funding), 30+ Centers of Excellence nationwide (every patient has access), 100+ fellows trained (AATD expertise no longer scarce)

**"Partner with the best minds to find the cure."**

---

**Explore Partnerships**

**Mark Egly Foundation Research & Partnerships**
üìß Email: research@markeglyfoundation.org
üìß Clinical Partnerships: clinicalnetwork@markeglyfoundation.org
üìû Phone: (XXX) XXX-XXXX
üåê Website: MarkEglyFoundation.org/Research

---

**Approved by**: Board of Directors
**Effective Date**: January 1, 2026
**Review Date**: Annually
**Version**: 1.0

---

_"Together with top institutions, we accelerate discovery."_

**‚Äî Mark Egly Foundation**
